###### Key messages

What is already known about this subject?
=========================================

-   The introduction of ACR/EULAR rheumatoid arthritis (RA) classification criteria has impacted positively on early diagnosis and treatment of RA leading to better outcomes. By the same token, broader criteria have led to the inclusion of patients with milder and more heterogenous disease. This, together with the inability to precisely predict disease prognosis and treatment response at the individual patient levels, emphasise the need to identify patients at risk of accelerated structural damage progression and fast-track aggressive/biological therapies to patients with poor prognosis.

###### Key messages

What does this study add?
=========================

-   This study analyses the largest biopsy-driven early inflammatory arthritis cohort to date (200 patients) and, through a detailed synovial cellular and molecular characterisation refines ACR/EULAR disease classification. In addition, the study identifies synovial pathobiological markers associated with the lympho-myeloid pathotype and the requirement of biological therapy at 12 months, reinforcing recently published data that indicate that these patients are affected by highly aggressive disease and worse radiographic outcome. Notably, these findings are independent from the time of diagnosis within the first 12 months of symptoms initiation, suggesting that the so-called 'window of opportunity' is wider than 6 months and early stratification of biological therapies according to poor prognostic synovial pathobiological subtypes at disease onset may improve the outcome of these patients. The integration of synovial pathobiological markers into a logistic regression model improves the prediction accuracy from 78.8% (clinical) to 89%--90% (clinical +molecular) and enables the identification at disease onset of patients who subsequently require biological therapy. Thus, this study provides support to the notion that biological therapies should be started early in patients with poor prognosis.

How might this impact on clinical practice or future developments?
==================================================================

-   The identification at disease onset of patients who are unlikely to respond to csDMARDs remains a major unmet need. The capacity to refine early clinical classification criteria through the application of synovial pathobiological markers and the ability to identify patients who subsequently require biological therapy at disease onset offer the opportunity to stratify therapeutic intervention to the patients most in need. This present study adds weight to the need to change current therapeutic algorithms and start biological therapies at disease onset in patients with poor prognosis. This is likely to have a major impact on disease control/remission and long-term disability, as notionally supported by numerous early intervention studies using biological therapies.

Introduction {#s1}
============

The introduction of new classification criteria for rheumatoid arthritis (RA) in 2010[@R1] has been demonstrated to be clinically useful with enhanced diagnostic sensitivity in early disease compared with 1987 criteria[@R2]; however, this is balanced by a lower specificity.[@R3] This is of particular importance, as data suggest that approximately 40% of patients with early inflammatory arthritis, not fulfilling 1987 criteria, may spontaneously remit while approximately 30% will progress to RA.[@R5] Critically, the mechanisms underlying the transition from undifferentiated arthritis (UA) to RA remain unknown though it has been suggested that qualitative or quantitative difference within synovial tissue may contribute to diverse disease evolution and/or treatment response.[@R6] Thus, pretreatment stratification of early inflammatory arthritis is important in order to target therapy to poor prognosis patients. Previous data suggest that stratifying early arthritis according to RA2010 versus RA1987 classification criteria reveals significant clinical heterogeneity in diagnosis at 2-year follow-up[@R8] although subsequent analysis of synovial tissue did not suggest that such clinical heterogeneity translated to significant differences in synovial pathobiology.[@R9] However, recently published data from a cohort of 144 patients with early RA have demonstrated that synovial cellular and molecular signatures define prognostic and treatment response phenotypes.[@R10] Importantly, whether clinical heterogeneity associated with the introduction of the 2010 ACR/EULAR criteria can be explained by synovial pathobiological signatures and whether they associate with subsequent disease outcome, up to now, remain unknown.

Therefore, the aim of this study was to investigate whether in patients with early inflammatory arthritis synovial cellular and molecular signatures: (1) segregate according to clinical classification (RA1987 vs RA2010 vs UA), (2) change depending on symptom duration and (3) determine prognosis including subsequent requirement for biological therapy.

Patients and methods {#s2}
====================

Patients {#s2-1}
--------

Two hundred consecutive patients with inflammatory arthritis recruited at Barts Health NHS Trust as part of the multicentre pathobiology of early arthritis cohort (<http://www.peac-mrc.mds.qmul.ac.uk>) were included within the study. Patients were treatment naïve (csDMARD and steroid) and had \<1 year symptoms.

At baseline, patients underwent collection of routine demographic data and were categorised according to the following criteria: (1) RA1987[@R2] or (2) UA. 2010 ACR/EULAR criteria for RA[@R1] were then applied to further classify patients with UA, resulting in three groups: (1) RA1987 (RA1987+/RA2010+), (2) RA2010 (RA1987−/RA2010+) and (3) UA (RA1987−/RA2010−). An ultrasound-guided synovial biopsy of a clinically active joint was performed.[@R11] Patients were then given standard conventional synthetic csDMARD therapy with a treat-to-target approach to treatment escalation (Disease Activity Score 28 joints (DAS28) \<3.2). Patients failing csDMARD therapy were given biological therapy (anti-tumour necrosis factor (TNF), tocilizumab or rituximab) according to the prevailing UK National Institute for Clinical Excellence (NICE) prescribing algorithm if they continued to have a DAS28 \>5.1 following 6 months of therapy.[@R12] At 12-month, follow-up patients were categorised as follows: (1) self-limiting (SL) disease (DAS28 \<3.2 and off csDMARD/steroid therapy) versus persistent disease (PD) (DAS28 \>3.2 and/or csDMARD) and (2) symptomatic treatment (non-steroidal anti-inflammatories) versus csDMARD therapy versus biological ±csDMARD therapy.

Synovial biopsy collection and processing {#s2-2}
-----------------------------------------

A minimum of six biopsies per patient were collected for paraffin embedding and if intact lining layer identified underwent histopathological assessment. Synovitis score was determined using a previously validated scoring system.[@R13] Following immunohistochemical staining of sequentially cut slides using previously reported protocols for B cells (CD20), T cells (CD3), macrophages (CD68) and plasma cells (CD138), the degree of immune cell infiltration was assessed semiquantitatively (0--4).[@R14] Biopsies were stratified into one of three synovial pathotypes according to the following criteria: (1) lympho-myeloid presence of grade 2--3 CD20 +aggregates, (CD20 ≥2) and/or CD138 \>2, (2) diffuse-myeloid CD68 SL ≥2, CD20 ≤1 and/or CD3 ≥1, CD138 ≤2 and (3) pauci-immune CD68 SL \<2 and CD3, CD20, CD138 \<1.

Nanostring analysis {#s2-3}
-------------------

A minimum of six synovial samples per patient were immediately immersed in RNA-Later and RNA extraction performed as previously described.[@R10] RNA samples then underwent profiling for the expression of 238 genes preselected based on previous microarray analyses of synovial tissue from patients with established RA[@R15] and/or relevance to RA pathogenesis. Raw NanoString counts were processed using the NanoStringQCPro package in R V.3.2.0. Counts were normalised for RNA content by global gene count normalisation and then log transformed (base 2). The validity of normalisation was then checked via box plot and scatter plot of normalised counts. Benjamini-Hochberg method was used to adjust for multiple testing, and genes were considered to be differentially expressed if they demonstrated an false discovery rate (FDR)-adjusted p\<0.01.

Statistical analysis {#s2-4}
--------------------

Statistical analyses were run using R V.3.0.2. For three-way comparisons, the Kruskal-Wallis test was used for continuous and χ^2^ or Fisher's exact test used for categorical variables as appropriate. A p\<0.05 was considered statistically significant. Post hoc comparison tests were performed using the Dunn test or Bonferroni correction as appropriate.

### Linear regression models {#s2-4-1}

Logistic regression using forward, backward and bidirectional stepwise selection was employed using the glm function in R.

Gene expression predictors were selected by L1 (LASSO) sparse logistic regression using R package glmnet. The penalty parameter λ was optimised using 10-fold cross validation. λ corresponding to the minimum mean cross-validated error was retained as final penalty parameter in the model.

### Predictive performance evaluation {#s2-4-2}

Predictive performance of the final prediction model was assessed by computing the area under the receiver operating characteristic curve (AUC), using both apparent and internal validation with 95% CI. Internal validation using a bootstrap method[@R16] (performed with R package boot version 1.3-18) was employed to correct for overfitting, to generate unbiased optimism-adjusted estimates of the C statistic (AUC) with low absolute error. Bootstrap estimate of the AUC statistic was computed by random sampling with replacement 500 times to enable estimation of the optimism corrected AUC.

Results {#s3}
=======

Patient demographics and clinical correlations {#s3-1}
----------------------------------------------

Two hundered pathobiology of early arthritis cohort patients were included: 128/200 (64%) patients were classified as RA1987 (RA1987+/RA2010+) and 72/200 (36%) as UA. Of the patients with UA, 25 were further classified as RA2010 (RA1987−/RA2010+) (25/200, 12.5%) and 47 remained as UA (RA1987−/RA2010−) (47/200, 23.5%) ([figure 1A](#F1){ref-type="fig"}). No significant difference in mean age, disease duration or erythrocyte sedimentation rate (ESR) between groups was demonstrated. However, the RA1987 group had significantly higher levels of C reactive protein (CRP), tender joint count (TJC), swollen joint count (SJC), DAS28, rheumatoid factor (RF), anticitrullinated protein antibody (ACPA) and Visual Analogue Score (VAS) and significantly higher numbers of patients seropositive for RF and ACPA compared with either the RA2010 or UA groups ([figure 1B](#F1){ref-type="fig"}). SJC and ACPA titres were the only clinical parameters with significant differences between the RA2010 and UA groups, indicating that in terms of clinical measures of disease activity these two groups are relatively homogenous.

![Baseline patient demographics. (A) Baseline classification of patients. Two hundred patients were classified into RA1987 versus UA. RA2010 ACR/EULAR criteria were then applied to patients with UA. Final 3 groups obtained showed 47 patients UA (RA1987−/RA2010−), RA2010 (RA1987−/RA2010+), RA1987 (RA1987+/RA2010+). (B) Demographics according to classification criteria. Data are presented as mean (SD) for continue variables and frequency and percentages for categorical variables. Baseline characteristics between the three groups were compared using the Kruskal-Wallis or Fisher's exact test as appropriate. For post hoc comparison, Dunn tests were run and p value from pairwise comparison reported in the last three columns of the table. ACPA titre, anticitrullinated protein antibody titre (IU/L); ACPA +ve, anticitrullinated protein antibody (\>20 IU/L); CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; ESR, erythrocyte sedimentation rate; RF titre, rheumatoid factor titre (IU/mL); RF +ve, rheumatoid factor serum positive (\>15 IU/L); 28TJC, 28 tender joint count; 28SJC, 28 swollen joint count.](annrheumdis-2019-215751f01){#F1}

Synovial pathotypes distinguish clinical phenotypes regardless of disease duration {#s3-2}
----------------------------------------------------------------------------------

Synovial biopsies were obtained predominantly from small joints (81.5%) ([figure 2A](#F2){ref-type="fig"}). Patients with synovial tissue suitable for histological analysis (166/200) were segregated according to baseline synovial pathotype ([figure 2B](#F2){ref-type="fig"}) and differences in clinical parameters evaluated. We demonstrated significantly higher mean DAS28 within the lympho-myeloid compared with either the diffuse-myeloid or pauci-immune group (5.82 vs 4.93 vs 4.86, p\<0.001). Mean CRP was significantly higher in the lympho-myeloid and diffuse-myeloid versus pauci-immune groups (16.86 vs 15.52 vs 9.55, p\<0.001) and a significantly higher number of patients were seropositive for either RF (p=0.012) or ACPA (p=0.011) within the lympho-myeloid group ([figure 2C](#F2){ref-type="fig"}). To evaluate whether disease duration influenced prevalence of synovial pathotype, patients were stratified into four groups according to disease duration at baseline (1--3 m, 4--6 m, 7--9 m and 10--12 m) and frequency of synovial pathotype determined. No significant differences in synovial pathotype frequency at each timepoint were demonstrated (p=0.65) ([figure 2D](#F2){ref-type="fig"}).

![Patient demographics and disease activity: comparison between pathotypes. (A) Number of biopsy procedures per joint. MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal. (B) Representative images of synovial pathotypes. Sections underwent immunohistochemical staining and semiquantitative scoring (0--4) to determine the degree of CD20 +B cells, CD3 +T cells, CD68 +lining) and sublining macrophage and CD138 +plasma cell infiltration. Sections were categorised into three pathotypes: (1) pauci-immune (CD68 SL \<2 and or CD3, CD20, CD138 \<1), (2) diffuse myeloid: (CD68SL \>2, CD20 \<1 and or CD3 \>1) and (3) lymphomyeloid: (grade 2--3 CD20 +aggregates, CD20 \>2). Arrow heads indicate positive stain cells. Empty arrows indicate B cell aggregates. (C) Demographic analysis by pathotype. Data are presented as mean and SD for numerical variables and frequency and percentage for categorical variables. Baseline characteristics between the three pathotypes were compared using a Kruskall-Wallis test and Fisher test (RF and ACPA positivity) as appropriate. Post hoc analysis for significant differences using the Dunn test for multiple comparison. A p value of \<0.05 was considered statistically significant. (D) Pathotype according to disease duration (months) at diagnosis. Absolute values (N) and percentage. A p value of \<0.05 was considered statistically significant. ACPA titre, anticitrullinated protein antibody titre (IU/L); ACPA +ve, anticitrullinated protein antibody (\>20 IU/L); CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; ESR, erythrocyte sedimentation rate; RF titre, rheumatoid factor titre (IU/mL); RF +ve, rheumatoid factor serum positive (\>15 IU/L); 28TJC, 28 tender joint count; 28SJC, 28 swollen joint count.](annrheumdis-2019-215751f02){#F2}

RA1987 patients display significantly higher levels of synovial immune cell infiltration compared to RA2010 and UA patients {#s3-3}
---------------------------------------------------------------------------------------------------------------------------

Patients were segregated according to pathotype and further into RA1987, RA2010 and UA categories. A higher proportion of patients within the RA1987 group were categorised as lympho-myeloid (vs diffuse myeloid or pauci-immune) (43.5% vs 33% vs 23.5%) ([figure 3A](#F3){ref-type="fig"}). We also demonstrated a significantly higher mean synovitis, CD3 +T cell, CD20 +B cell, CD138 +plasma cell and CD68 +SL/L macrophage score between the RA1987 group and both the RA2010 and UA groups (p\<0.001) ([figure 3B](#F3){ref-type="fig"}). We saw no significant differences in synovitis score, mean CD3 +T, CD20 +B, CD68 +L or SL macrophage or CD138 +plasma cell number between the RA2010 and UA group ([figure 3B](#F3){ref-type="fig"}), indicating that these two groups are relatively homogenous in terms of tissue pathology.

![Variation in synovial pathobiology according to clinical classification of patients. (A) Baseline clinical classification compared with pathotype. Baseline subgroups (RA1987, RA2010 and UA) were compared with pathotype. Fisher test used for analysis. (B) Immune cell infiltration for each clinical subgroup. Kruskal-Wallis test for comparison between three groups. Post hoc analysis for significant differences using the Dunn test for multiple comparison. (C) (C--E) Gene expression analysis for comparison between subgroups. t-Test for comparison and volcano plot for representative image. Positive values represent upregulation and negative values downregulation. Green circles above green horizontal line represents non-corrected for multiple analysis expressed genes between groups. Red circles above red line represents corrected p values (Benjamini-Hochberg (BH) method) for multiple analysis. (C) Volcano plot RA1987 versus RA2010: difference in gene expression between patient fulfilling RA 1987 ACR criteria and RA 2010 ACR/EULAR criteria. (D) Volcano plot RA1987 versus UA: difference in gene expression between patient fulfilling RA 1987 ACR criteria and UA. (E) Volcano plot RA 2010 versus UA: differences in gene expression between patient fulfilling RA 2010 ACR/EULAR criteria and UA. RA, rheumatoid arthritis; UA, undifferentiated arthritis.](annrheumdis-2019-215751f03){#F3}

Synovial genes regulating B cell activation and function are significantly upregulated in RA1987 patients compared to the RA2010/UA groups {#s3-4}
------------------------------------------------------------------------------------------------------------------------------------------

Of 200 patients, 145 had RNA available for Nanostring analysis (95/128 RA1987 patients, 12/25 RA2010 patients and 38/47 patients with UA) and were analysed for differential gene expression (238 genes) between groups.

Comparing RA1987 versus RA2010 groups, we demonstrated a significant differential expression of 53 genes ([figure 3C](#F3){ref-type="fig"}). In line with the histological analysis, a number of differentially upregulated genes within the RA1987 cohort were involved in mediating B cell activation/function (eg, *CD79A*, *CD38*, *IGJ*, *CXCL13*, *IRF4*, *CCL19*, *CD38*, *TNFA* and *IL6*). When evaluating gene expression between RA1987 and UA groups, we found a similar trend with differential upregulation of a number of genes within the RA1987 cohort mediating B cell activation/function although only *CXCL13* remained significant following correction for multiple comparisons ([figure 3D](#F3){ref-type="fig"}). Conversely, when evaluating gene expression between the RA2010 and UA cohorts, only seven genes appeared as significant with a preponderance of differentially upregulated genes within the RA2010 cohort mediating cartilage biology (*COMP*, *DKK3*, *INHBA*) and none remaining significant after correction for multiple comparisons ([figure 3E](#F3){ref-type="fig"}).

Classification as RA1987 criteria at disease onset predicts PD at 12 months {#s3-5}
---------------------------------------------------------------------------

Of 200 patients, 190 had 12-month follow-up data available; we examined whether baseline synovial pathotype was associated with disease evolution. 119/121 (99%) RA1987 patients and 19/22 (90%) RA2010 had PD ([figure 4A](#F4){ref-type="fig"}). Within the UA cohort, 11/47 (23%) had other diagnoses. Of the remaining 36 patients, 26/36 (72.2%) had PD, and 10/36 (27.8%) SL. Of the patients with UA with PD, 4/26 (15.3%) progressed to fulfil 2010 ACR/EULAR criteria RA at 12 months. Results demonstrated a significantly higher proportion of patients with SL disease in the UA group compared with the RA2010 or RA1987 groups and a significantly higher number of patients within the RA1987 group with PD ([figure 4B](#F4){ref-type="fig"}). When evaluating the effect of baseline pathotype, we demonstrated a higher proportion of patients with a lympho-myeloid versus diffuse-myeloid or pauci-imune pathotype (39% vs 32% vs 13%) with PD and a higher number of patients with a diffuse-myeloid versus lympho-myeloid or pauci-immune pathotype (54% vs 18% vs 27%) with SL ([figure 4C](#F4){ref-type="fig"}).

![Disease evolution. (A) Patient classification after 12-month follow-up. Disease outcome after 12 months of follow-up for each of the initial baseline subgroups (RA1987/RA2010/UA). Disease evolution classified as self-limiting or persistent disease. Other diagnosis as described for those who were reclassified after 1 year form UA cohort. (B) Disease evolution by subgroups. Disease evolution was compared with baseline subgroups (RA1987, RA2010 and UA). Fisher test used for analysis. (C) Disease evolution by pathotype. Disease evolution was compared with pathotype (pauci-immune vs diffuse myeloid vs lymphomyeloid). Fisher test used for analysis. A p value of \<0.05 was considered statistically significant. RA, rheumatoid arthritis; UA, undifferentiated arthritis.](annrheumdis-2019-215751f04){#F4}

A baseline lympho-myeloid pathotype significantly associates with 12-month requirement for biological therapy {#s3-6}
-------------------------------------------------------------------------------------------------------------

Patients stratified according to diagnostic group or pathotype were further classified according to 12-month treatment requirement: (1) symptomatic treatment, (2) csDMARDs or (3) biologics±csDMARDs. A significantly higher proportion of RA1987 patients required biologic compared with RA2010 and UA (27.82% vs 20.83% vs 10.63%) (p\<0.001) ([figure 5A](#F5){ref-type="fig"}) and importantly, lympho-myeloid (vs diffuse-myeloid or pauci-immune) pathotype significantly associated with 12-month requirement for biological therapy (57% vs 21% vs 21% p=0.02) ([figure 5B](#F5){ref-type="fig"}).

![(A) Comparison between diagnostic subgroups and treatment outcome at 12-month follow-up. Treatment required was divided in three groups: (1) no treatment; (2) csDMARDs only, and (3) csDMARDs ±biologics. Fisher test for analysis. (B) Comparison between pathotype and treatment outcome at 12 months. (C) Gene expression analysis, represented in a volcano plot comparison between patient requiring biologics versus non-biological group. t-Test comparison for gene difference expression between groups. Positive values represent upregulation and negative values downregulation. An adjusted (Benjamini-Hochberg (BH) correction for multiple analysis) p value of \<0.01 was considered statistically significant, represented as dots above red line. Green dots above green line for gene expression significance when no correction applied for multiple analysis (p\<0.05). (D) Treatment outcome according to baseline disease duration. Fisher test for analysis. (E) Pathotype according to baseline disease duration for biological patient cohort. Fisher test for analysis. A p value of \<0.05 was considered statistically significant unless otherwise stated. RA, rheumatoid arthritis; UA, undifferentiated arthritis.](annrheumdis-2019-215751f05){#F5}

We then compared expression of the 238 genes in the Nanostring panel between patients requiring biological therapy (n=34) or not (n=106) and found 119 differentially expressed genes. Patients requiring biological therapy had significantly higher differential upregulation of genes regulating B and T cell proliferation, differentiation and activation (eg, *TNFRSF13C, CD79A, CD2, CD3E* and *CD38*), genes involved in matrix metallopeptidase production/regulation (eg, *MMP1* and *TIMP1*), genes involved in cytokine-mediated cellular activation (*TNFA, TRAF3IP3, IFNA1*) and osteoclastogenesis inhibition (*DEF6*). Patients who did not require biological therapy expressed some B and T cell regulation genes and B proliferation markers but mostly markers of fibroblast proliferation and cartilage turnover ([figure 5C](#F5){ref-type="fig"}).

To determine whether disease duration influenced outcome, we segregated patients according to 12-month treatment (biological therapy or not) and further into disease duration quartiles ([figure 5D](#F5){ref-type="fig"}) and demonstrated no significant differences in terms of disease duration at diagnosis. Next, we segregated patients treated with biological therapy (n=39) according to quartiles of disease duration and then synovial pathotype. We found no significant differences in patient number in each quartile (p=0.3) ([figure 5E](#F5){ref-type="fig"}). These results strongly suggest that synovial pathotype rather than disease duration influences 12-month treatment outcome.

Synovial gene expression signatures enhance the performance of clinical prediction models for biological requirement {#s3-7}
--------------------------------------------------------------------------------------------------------------------

To determine whether baseline clinical and gene expression data could be combined into a model for predicting requirement for biological therapy, we used two complementary approaches: a logistic regression model to identify predictive clinical covariates, and a penalised method based on logistic regression with an L1 regularisation penalty (LASSO) to identify genes improving the clinical model.

Nine baseline clinical covariates were considered as candidates in the regression model: disease duration, ESR, CRP, RF, ACPA, TJC, SJC, DAS28 and pathotype (two categories, lympho-myeloid vs pauci-immune/diffuse-myeloid). Logistic regression models using backward forward and bidirectional stepwise selection resulted in the selection of the same set of clinical covariates: DAS28, pathotype, CRP and TJC. The apparent predictive performance of the model evaluated by AUC was 0.78 (95% CI 0.70 to 0.87).

Genes were selected to improve the clinical model using logistic regression with an L1 regularisation penalty (LASSO) applied on the four clinical covariates selected by the previous logistic regression and the 119 genes identified as being significantly differentially expressed between the biological and non-biological groups. Models in which clinical predictors were penalised or subject to forced inclusion were compared. When all predictors were penalised, 11 predictors were retained in the final model and when the clinical covariates were not penalised, 13 predictors were retained ([figure 6A](#F6){ref-type="fig"}). In both the penalised and unpenalised clinical model, the apparent prediction performance was improved (apparent AUC=0.89, 95% CI 0.83 to 0.95 and AUC=0.90, 95% CI 0.84 to 0.95) ([figure 6B](#F6){ref-type="fig"}). We additionally performed internal validation to correct the AUC performance measure for overfitting by calculating the optimism of the AUC for each model by bootstrapped sampling with replacement from the original dataset. The optimism corrected AUC was 0.75 for the pure clinical model and 0.81 for the clinical and gene model (LASSO) ([figure 6C and D](#F6){ref-type="fig"}) suggesting that including both clinical covariates and genes in the model results in an improvement of the predictive ability of the model.

![Prediction model. (A) and (B) Identification of clinical and gene expression features predictive of biological therapy use at 1 year. Logistic regression, coupled with backward and stepwise model selection, was applied to baseline clinical parameters against a dependent variable of biological therapy use or not at 12 months to select which clinical covariate contributed the most to the prediction. Selected covariates (119 genes+4 clinical covariates) were entered simultaneously into a logistic model with an L1 regularisation penalty (LASSO) in order to determine the optimal sparse prediction model. A similar predictive performance of the model when clinical was seen when results were penalised (blue-dashed line, A) than when they were not penalised (red-dotted line, A) with a slightly different set of selected covariates (B). (B) Non-zero weights associated with the final variables selected by the LASSO regression. The grey spaces represent the variables that were not selected by the model. (C) and (D) Lambda training curve from the final glmnet fitted model. The red dots represent mean binomial deviance using 10-fold cross validation. The error bars represent SE of binomial deviance. The vertical dotted lines indicate minimum binomial deviance (λ~min~) and a more regularised model for which the binomial deviance error is within one SE of the minimum binomial deviance (λ~1se~). λ~min~ was selected, corresponding to 11 non-zero coefficients in the final model for the LASSO where clinical were penalised (C) and 13 non-zero coefficients in the final model for the LASSO where clinical were not penalised (D). AUC, area under the receiver operating characteristic curve; CRP, C reactive protein; DAS28, Disease Activity Score 28 joints; TJC, tender joint count.](annrheumdis-2019-215751f06){#F6}

Discussion {#s4}
==========

These results present a number of novel findings: first, they strongly suggest that patients with early inflammatory arthritis not fulfilling RA1987 criteria display similar clinical, synovial histological and molecular features irrespective of further classification according to RA2010 or UA criteria. Second, these data also suggest that a lympho-myeloid pathotype at disease onset predicts poor outcome with patients subsequently requiring biological therapy irrespective of clinical classification, and finally that the integration of histological and molecular signatures into a clinical prediction model enhances sensitivity/specificity for predicting whether patients will require biological therapy.

To the best of our knowledge, these results emerge from the largest synovial tissue treatment-naïve early arthritis cohort reported to date and support previous data from early RA cohorts suggesting that a synovial immune cell infiltrate characterised by a predominant infiltrate of B cells associates with more active disease[@R18] and seropositivity for RF and ACPA.[@R10] The results suggest that this effect also extends to patients within the UA cohort. The clinical similarities between RA2010+/RA1987− patients and those with UA have been reported previously[@R8] and the data presented herein provide a pathophysiological explanation for this with the demonstration of homogeneous synovial cellular and molecular signatures among the two groups. The data show a lower percentage of patients requiring biological therapy in RA2010+/RA1987− group, in line with the expectation that the ACR/EULAR 2010 criteria enable an earlier diagnosis and thus efficacious treatment. However, it is also possible that this group has a milder pathology from the beginning.

Although synovial pathotypes per se do not appear to distinguish between patients at risk of developing PD rather than SL disease, this is not surprising given the early and treat-to-target approach pursued in the study rather than observing untreated natural disease evolution. However, when applying 12-month biological requirement as a prognostic outcome, we demonstrated that patients with a lympho-myeloid pathotype with a dense synovial infiltrate enriched in B cells and significant upregulation of T/B cell genes at disease onset predicted requirement for subsequent biological therapy and critically that this was independent of disease duration. These results are consistent with recently published data in early RA which reports that the lympho-myeloid pathotype is associated with highly agressive disease and worse radiographic outcomes.[@R10] The current study reinforces these findings demonstrating that, at 12-month follow-up, a significantly higher proportion of patients classified as lympho-myeloid pathotype required biological therapy. The study also calls into question the current dogma surrounding 'an early window of opportunity' for all patients with RA,[@R19] suggesting that pathotype rather than simply disease duration influences outcome and that intensive therapeutic regimens should be targeted to poor prognostic pathotypes. This notion is supported by the demonstration that the integration of synovial histological and molecular markers into a clinical prediction model for biologics use improves sensitivity/specificity from 78.8% to 89%--90% independently from disease duration.

Discrepancy with previously reported data suggesting that synovial heterogeneity does not relate to clinical phenotypes[@R9] maybe explained by the fact that in our study the majority of biopsies were performed on small joints while in that cohort arthroscopic biopsy was restricted to patients with mainly large joint involvement and, thus, a potential selection bias.[@R22] Additionally, the paired histological and molecular data in the largest biopsy-driven early arthritis cohort reported to date ensured internal validation and high classification accuracy.

Our study does have limitations however, for example, the real-life nature of the study did not permit the true evaluation of the natural history of the disease or outcome, as no patients were left untreated and therapy was not actively withdrawn. Also, a treat-to-target approach, treatment escalation and initiation of biological therapy, was determined by treating physicians according to NICE guidelines rather than study protocol.

Within these limitations, our results are robust and suggest that the introduction of the new RA2010 classification criteria brings additional clinical and biological heterogeneity into early patient classification compared with the 1987 criteria with limited ability of RA2010 criteria alone to predict poor outcome. The demonstration that the integration of synovial pathobiological markers into clinical algorithms predicting poor outcome (requirement for biological therapy) independent of disease duration suggests that the 'window of opportunity' is wider than 6 months and early stratification of biological therapies according to poor prognostic synovial pathobiological subtypes at disease onset may improve the outcome of these patients.
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